Background: The present study aimed to assess the efficacy of omega-3 in treating ROP in premature
Methods: This randomized double-blinded controlled trial was performed on 160 premature infants with gestational
age lower than 32 weeks and birth weight < 1500 grams who were at risk of ROP development (Tehran,
Iran-2013). Children were randomly assigned to two groups. The intervention group received 300 mg omega-3
daily and the control group received sterile water as the placebo. The severity of ROP was defined according to
the International Classification of ROP.
Results: The frequency of ROP was 7.5% in the group received omega-3 and 20.0% in the placebo group with a
significant difference (p = 0.021). Regarding the severity of ROP in the intervention group, ROP grade I was
found in two patients and ROP grade II in four patients; while ROP grade I, II, and III were revealed in 6, 6, and 4
patients in placebo group indicating a significant difference between the two groups (p = 0.001). Using the multivariate
logistic regression modeling with the presence of gender, gestational age, and birth weight, the use of
omega-3 was associated with reduced risk for ROP (p = 0.045).
Conclusion: The use of omega-3 supplement can be an appropriate treatment option for the treatment of ROP in